Randomized trial evaluates in vitro diagnostic tests for Chagas disease, indicating high quality standards for diagnosis.
Key Points
This research aims to evaluate the quality of in vitro diagnostic tests for Chagas disease as part of the registration process with Anvisa.
A survey analyzed clinical sensitivity and specificity of tests at the National Institute for Health Quality Control from January 2023 to December 2025.
Tests that met sensitivity of 100% and specificity of at least 99% were deemed satisfactory.
20 batches of various diagnostic tests were assessed, including rapid tests and chemical assays.
19 out of 20 batches (95%) met the recommended sensitivity and specificity thresholds.
Only 1 batch (5%) received an unsatisfactory rating for efficacy.
All tests received were for pre-marketing analysis.